|Program||Target(s)||Indication(s)||Discovery||IND-enabling||Phase 1||Phase 2||Phase 3||Commercial rights|
|CRG-022 (CAR T)||CD22||R/R LBCL - post CD19 CAR T|
|CRG-022 (CAR T)||CD22||LBCL - CAR T naïve(1)|
|CRG-022 (CAR T)||CD22||Pediatric B-ALL|
|CRG-023 (tri-specific CAR T with CD2 co-stimulation)||CD19
CARGO is developing multi-specific CAR T-cell therapies with CD2 co-stimulation designed to overcome multiple resistance mechanisms – antigen loss, co-stimulation (CD58) loss and lack of persistence. With a multi-targeted approach, it has the potential to treat several hematologic malignancy types.
Our most advanced preclinical program, CRG-023, incorporates a tri-specific CAR to address either tumor antigen loss (e.g., CD19) or low-density antigen expression, loss of costimulation (e.g., CD58) and lack of T-cell persistence. CRG-023 is designed to target tumor cells with three B-cell antigen targets, CD19, CD20 and CD22. This product candidate also integrates a CD2 costimulatory domain into the tri-specific CAR T-cell to counter a target-independent mechanism, the downregulation of COSS (the ligand of the CD2 costimulatory receptor), that leads to resistance to CAR T-cells and other immune therapies.